Skip Ribbon Commands
Skip to main content
Navigate Up
Sign In
Scott D. Lee, MD
Associate Professor & Director,
Clinical Inflammatory Bowel Disease Program
Biography
Dr. Lee is an associate professor of medicine with expertise in inflammatory bowel disease (Crohn's disease and ulcerative colitis). Dr. Lee earned his bachelor's degree at Pomona College and his M.D. at Jefferson Medical College. He completed his residency in internal medicine at the University of Colorado in Denver. After residency, Dr. Lee completed his gastroenterology fellowship at the University of Washington. After completing his fellowship, he attended the University of Chicago and Cedar-Sinai in Los Angeles as a visiting physician to gain additional training in IBD. Since finishing his fellowship, he has been an attending gastroenterology physician at the University of Washington Medical Center.
 
Currently his clinical practice is at the Digestive Health Center at the University of Washington and is dedicated almost exclusively to providing care to patients with the diagnosis of IBD. His research is focused on inflammatory bowel diseases (IBD) including – new therapies for IBD, improving outcomes in the treatment and long term management of IBD, evaluation of non-invasive biomarkers to assess disease activity in IBD patients and the effects of the microbiome on IBD. He has participated in more than 100 clinical trials in IBD and continues to have an active clinical research program.
 
He is a member of the Crohn's Colitis Foundation of America (CCFA), American Gastroenterology Association, American College of Gastroenterology and American Society of Gastrointestinal Endoscopy. He is a past chair of Northwest CCFA Chapter Medical Advisory Committee (CMAC) and continues as a current member of the CMAC.
 
Recent Publications
Displaying 20 Most Recent Publications from PubMed

May 2018. A phase 2, Randomized, Placebo-controlled Study Evaluating Matrix Metalloproteinase-9 Inhibitor, Andecaliximab, in Patients with Moderately to Severely Active Crohn's Disease. Schreiber S, Siegel CA, Friedenberg KA, Younes ZH, Seidler U, Bhandari BR, Wang K, Wendt E, McKevitt M, Zhao S, Sundy JS, Lee SD, Loftus EV Jr. J Crohns Colitis. 2018 May 29. doi: 10.1093/ecco-jcc/jjy070. [Epub ahead of print]

April 2018. Outcomes of Therapy for Vulvar Manifestation of Inflammatory Bowel Disease in Adolescents. Debiec KE, Lee SD, Wahbeh GT, Amies Oelschlager AM. J Pediatr Adolesc Gynecol. 2018 Apr;31(2):149-152. doi: 10.1016/j.jpag.2017.08.008. Epub 2017 Sep 15.

April 2018. Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease. Fleisher M, Marsal J, Lee SD, Frado LE, Parian A, Korelitz BI, Feagan BG. Dig Dis Sci. 2018 Apr;63(4):825-833. doi: 10.1007/s10620-018-4971-1. Epub 2018 Feb 26.

July 2017. Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's Disease. Sandborn WJ, Wolf DC, Kosutic G, Parker G, Schreiber S, Lee SD, Abraham B, Afzali A, Arsenescu RI, Gutierrez A, Spearman M, Coarse J, Feagan BG. Inflamm Bowel Dis. 2017 Jul;23(7):1047-1056. doi: 10.1097/MIB.0000000000001100.

January 2017. Reply. Afzali A, Sinanan MN, Lee SD. Inflamm Bowel Dis. 2017 Jan;23(1):E3. doi: 10.1097/MIB.0000000000000985.

November 2016. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease. Feagan BG, Sandborn WJ, Gasink C, Jacobstein D, Lang Y, Friedman JR, Blank MA, Johanns J, Gao LL, Miao Y, Adedokun OJ, Sands BE, Hanauer SB, Vermeire S, Targan S, Ghosh S, de Villiers WJ, Colombel JF, Tulassay Z, Seidler U, Salzberg BA, Desreumaux P, Lee SD, Loftus EV Jr, Dieleman LA, Katz S, Rutgeerts P; UNITI–IM-UNITI Study Group. N Engl J Med. 2016 Nov 17;375(20):1946-1960.

August 2016. Preoperative Use of Methotrexate and the Risk of Early Postoperative Complications in Patients with Inflammatory Bowel Disease. Afzali A, Park CJ, Zhu K, Hu JK, Sharma P, Sinanan MN, Lee SD. Inflamm Bowel Dis. 2016 Aug;22(8):1887-95. doi: 10.1097/MIB.0000000000000780.

August 2016. Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study. Lee SD, Rubin DT, Sandborn WJ, Randall C, Younes Z, Schreiber S, Schwartz DA, Burakoff R, Binion D, Dassopoulos T, Arsenescu R, Gutierrez A, Scherl E, Kayhan C, Hasan I, Kosutic G, Spearman M, Sen D, Coarse J, Hanauer S. Inflamm Bowel Dis. 2016 Aug;22(8):1870-80. doi: 10.1097/MIB.0000000000000805.

March 2016. O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohn's Disease Refractory to Anti-TFNα: UNITI-1. Sandborn W, Gasink C, Blank M, Lang Y, Johanns J, Gao LL, Sands B, Hanauer S, Feagan B, Targan S, Ghosh S, de Villiers W, Colombel JF, Lee S, Desreumaux P, Loftus E Jr, Vermeire S, Rutgeerts P. Inflamm Bowel Dis. 2016 Mar;22 Suppl 1:S1. doi: 10.1097/MIB.0000000000000720.

November 2015. Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease. Feagan BG, Sandborn WJ, D'Haens G, Lee SD, Allez M, Fedorak RN, Seidler U, Vermeire S, Lawrance IC, Maroney AC, Jurgensen CH, Heath A, Chang DJ. Aliment Pharmacol Ther. 2015 Nov;42(10):1170-81. doi: 10.1111/apt.13398. Epub 2015 Sep 23.

August 2015. Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study. Sandborn WJ, Melmed GY, McGovern DP, Loftus EV Jr, Choi JM, Cho JH, Abraham B, Gutierrez A, Lichtenstein G, Lee SD, Randall CW, Schwartz DA, Regueiro M, Siegel CA, Spearman M, Kosutic G, Pierre-Louis B, Coarse J, Schreiber S. Aliment Pharmacol Ther. 2015 Aug;42(3):330-42. doi: 10.1111/apt.13251. Epub 2015 Jun 1.

June 2015. Briakinumab for treatment of Crohn's disease: results of a randomized trial. Panaccione R, Sandborn WJ, Gordon GL, Lee SD, Safdi A, Sedghi S, Feagan BG, Hanauer S, Reinisch W, Valentine JF, Huang B, Carcereri R. Inflamm Bowel Dis. 2015 Jun;21(6):1329-40. doi: 10.1097/MIB.0000000000000366.

June 2014. The association of psoriasiform rash with anti-tumor necrosis factor (anti-TNF) therapy in inflammatory bowel disease: A single academic center case series. Afzali A, Wheat CL, Hu JK, Olerud JE, Lee SD. J Crohns Colitis. 2014 Jun;8(6):480-8. doi: 10.1016/j.crohns.2013.10.013. Epub 2013 Nov 21.

August 2013. Vedolizumab as induction and maintenance therapy for Crohn's disease. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group. N Engl J Med. 2013 Aug 22;369(8):711-21. doi: 10.1056/NEJMoa1215739.

March 2013. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, Ullman T, Glover S, Valentine JF, Rubin DT, Miller J, Abreu MT. Clin Gastroenterol Hepatol. 2013 Mar;11(3):286-92. doi: 10.1016/j.cgh.2012.11.011. Epub 2012 Nov 28.

March 2013. The pediatric pouch in inflammatory bowel disease: a primer for the gastroenterologist. Wahbeh GT, Suskind DL, Lee SD, Waldhausen JT, Murray KF. Expert Rev Gastroenterol Hepatol. 2013 Mar;7(3):215-23. doi: 10.1586/egh.12.70.

December 2012. Prospective study of the progression of low-grade dysplasia in ulcerative colitis using current cancer surveillance guidelines. Zisman TL, Bronner MP, Rulyak S, Kowdley KV, Saunders M, Lee SD, Ko C, Kimmey MB, Stevens A, Maurer J, Brentnall TA. Inflamm Bowel Dis. 2012 Dec;18(12):2240-6. doi: 10.1002/ibd.22912. Epub 2012 Apr 16.

March 2012. A review and expert opinion of the use of certolizumab for Crohn's disease. Evans AT, Lee SD. Expert Opin Biol Ther. 2012 Mar;12(3):363-70. doi: 10.1517/14712598.2012.658770.

January 2012. Co-morbid diabetes in patients with Crohn's disease predicts a greater need for surgical intervention. Harper JW, Welch MP, Sinanan MN, Wahbeh GT, Lee SD. Aliment Pharmacol Ther. 2012 Jan;35(1):126-32. doi: 10.1111/j.1365-2036.2011.04915.x. Epub 2011 Nov 10.

October 2011. Novel jumbo biopsy forceps for surveillance of inflammatory bowel disease: a comparative retrospective assessment. Song K, Toweill D, Rulyak SJ, Lee SD. Gastroenterol Res Pract. 2011;2011:671659. doi: 10.1155/2011/671659. Epub 2011 Oct 9.

June 2011. Long-term therapy with sargramostim in a patient with Crohn's disease. Wong AC, Lee SD. Inflamm Bowel Dis. 2011 Jun;17(6):1447-8. doi: 10.1002/ibd.21542. Epub 2010 Nov 8.

May 2010. Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Sandborn WJ, Abreu MT, D'Haens G, Colombel JF, Vermeire S, Mitchev K, Jamoul C, Fedorak RN, Spehlmann ME, Wolf DC, Lee S, Rutgeerts P. Clin Gastroenterol Hepatol. 2010 Aug;8(8):688-695.e2. Epub 2010 May 6.

April 2008. Complications after ERCP in patients with primary sclerosing cholangitis. Etzel JP, Eng SC, Ko CW, Lee SD, Saunders MD, Tung BY, Kimmey MB, Kowdley KV Gastrointest Endosc. 2008 Apr;67(4):643-648. Epub 2007 Dec 3

February 2008. Prevalence of and risk factors for vitamin B(12) deficiency in patients with Crohn's disease. Headstrom PD, Rulyak SJ, Lee SD Inflamm Bowel Dis. 2008 Feb;14(2):217-23

July 2007. Successful endoscopic treatment of Bouveret's syndrome with intracorporeal electrohydraulic lithotripsy. Huebner ES, DuBois S, Lee SD, Saunders MD Gastrointest Endosc. 2007 Jul;66(1):183-4; discussion 184. Epub 2007 May 23

April 2007. Incidence of minor complications and time lost from normal activities after screening or surveillance colonoscopy. Ko CW, Riffle S, Shapiro JA, Saunders MD, Lee SD, Tung BY, Kuver R, Larson AM, Kowdley KV, <br>Kimmey MB Gastrointest Endosc. 2007 Apr;65(4):648-656. Epub 2006 Dec 14

November 2004. A randomized controlled trial of gastric lavage prior to endoscopy for acute upper gastrointestinal bleeding. Lee SD, Kearney DJ. J Clin Gastroenterol. 2004 Nov-Dec;38(10):861-5.

July 2003. Clinical correlation of toxin and common antigen enzyme immunoassay testing in patients with Clostridium difficile disease. Lee SD, Turgeon DK, Ko CW, Fritsche TR, Surawicz CM. Am J Gastroenterol. 2003 Jul;98(7):1569-72.

March 2003. Hepatotoxicity associated with 6-thioguanine therapy for Crohn's disease. Rulyak SJ, Saunders MD, Lee SD. J Clin Gastroenterol. 2003 Mar;36(3):234-7.

November 2002. Maintenance infliximab infusions forever? Lee SD, Surawicz CM. Am J Gastroenterol. 2002 Nov;97(11):2917-8.

Contact Info
Education

M.D., Jefferson Medical College, Philadelphia, PA

Residency in Medicine, University of Colorado, Denver, CO

Fellowship in Gastroenterology, University of Washington, Seattle, WA

©2016-2018 University of Washington Division of Gastroenterology
1959 NE Pacific St., Box 356424, Seattle, WA 98195-6424
Contact Us | Privacy | Terms | Copyright & Disclaimer